TENAYA THERAPEUTICS TNYA 深 沪
等待开盘 09-29 09:30:00 美东时间
1.66
+0.170
+11.41%
华盛通- 最 高1.68
- 今 开1.50
- 成交量 445.30万股
- 最 低 1.48
- 昨 收 1.49
- 总市值 2.71亿
- 52周最高 4.01
- 市盈率 静 --
- 换手率 2.73%
- 52周最低 0.36
- 委 比 -94.51%
- 总股本 1.63亿
- 历史最高 32.00
- 量 比 1.22
- 振 幅 13.42%
- 历史最低 0.36
- 每 手 1
- 风险率 1.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics granted stock options to purchase 202,000 shares of its common stock to two new non-executive employees. The options, exercisable at $1.20 per share, vest over four years and are subject to the company's 2024 Inducement Equity Incentive Plan. The options, granted as inducements under NASDAQ Listing Rule 5635(c)(4), reflect the company's mission to develop curative therapies for heart disease.
09-18 20:05
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
09-08 17:59
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Tenaya Therapeutics' CEO, Faraz Ali, will participate in a fireside chat at Morgan Stanley's 23rd Annual Global Healthcare Conference on September 9, 2025. The event will be webcast live and available for replay on Tenaya's website. Tenaya focuses on developing curative therapies for heart disease, with a pipeline including gene therapies TN-201 and TN-401, and small molecule HDAC6 inhibitor TN-301. For more details, visit their website or contac...
09-02 20:05
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
Tenaya Therapeutics presented interim data from its MyClimb study, the largest noninterventional natural history study of pediatric participants with MYBPC3-associated hypertrophic cardiomyopathy (HCM), at the European Society of Cardiology Congress. The study highlights the severe risks and rapid progression of the disease, particularly in nonobstructive HCM, which lacks approved treatments. Key findings include: 93% of participants had nonobstr...
08-31 14:15
HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 price target.
08-27 18:15
Analysts’ Top Healthcare Picks: Tenaya Therapeutics (TNYA), Nexalin Technology, Inc. (NXL)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-21 17:03
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Tenaya Therapeutics' CEO, Faraz Ali, will speak at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The event will be webcast live and available via the Investors section of Tenaya's website, with an archive for 30 days. Tenaya focuses on developing curative therapies for heart diseases, with clinical-stage candidates TN-201 and TN-401 targeting genetic cardiomyopathies. The company leverages genetic insights and innovative...
08-08 12:00
Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
08-07 20:50
Tenaya Therapeutics Q2 EPS $(0.14) Beats $(0.17) Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 58.82 percent increase over losses of $(0.34) per share
08-07 05:13
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Tenaya Therapeutics announced the completion of enrollment and positive safety reviews for its gene therapy trials for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The Data Safety Monitoring Board recommended dose escalation and expansion for both TN-201 and TN-401 trials, with initial data expected in the fourth quarter of 2025. The company reported a cash runway ...
08-06 20:30
